Hydrogen sulfide provides intestinal protection during a murine model of experimental necrotizing enterocolitis
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Jan 2018 · 1 min read
In brief
In brief
Experimental study testing hydrogen sulfide donors as a novel therapeutic approach for necrotizing enterocolitis in a neonatal mouse model. Researchers evaluated three H2S compounds for their ability to improve intestinal perfusion, reduce tissue injury, and enhance clinical outcomes in NEC.
Written by the GCMD Library team from the article.
Background
Necrotizing enterocolitis (NEC) continues to be a morbid surgical condition among preterm infants. Novel therapies for this condition are desperately needed. Hydrogen sulfide (H2S) is an endogenous gasotransmitter that has been found to have beneficial properties. We therefore hypothesized that intraperitoneal injection of various H2S donors would improve clinical outcomes, increase intestinal perfusion, and reduce intestinal injury in an experimental mouse model of necrotizing enterocolitis.
Methods
NEC was induced in five-day-old mouse C57BL/6 mouse pups through maternal separation, formula feeding, and intermittent hypoxic and hypothermic stress. The control group (n=10) remained with their mother and breastfed ad lib. Experimental groups (n=10/group) received intraperitoneal injections of phosphate buffered saline (PBS) vehicle or one of the following H2S donors: (1) GYY4137, 50mg/kg daily; (2) Sodium sulfide (Na2S), 20mg/kg three times daily; (3) AP39, 0.16mg/kg daily. Pups were monitored for weight gain, clinical status, and intestinal perfusion via transcutaneous Laser Doppler Imaging (LDI). After sacrifice on day nine, intestinal appearance and histology were scored and cytokines were measured in tissue homogenates of intestine, liver, and lung. Data were compared with Mann–Whitney and p